UK Pharma Group Worries About Post-Brexit Supply Chain Security

A new EU safety net for snaring illicit drugs went into effect on Feb. 9 — but the UK may not be under its protection for very long, according to the Association of the British Pharmaceutical Industry (ABPI).

The biopharmaceutical group is concerned that patients will become more vulnerable to fake and falsified medicines if the UK leaves the EU without an agreement on March 29 and is no longer part of the new system that implements the EU’s Falsified Medicines Directive (FMD).

“Brexit uncertainty means that organizations across the UK’s medicines supply chain don’t know whether the system will still be in place in seven-weeks’ time as a ‘no deal’ Brexit would mean a UK revocation of the FMD legislation,” the association said.